



## Corrigendum

## Corrigendum to “Correlation of tumor spread through air spaces and clinicopathological characteristics in surgically resected lung adenocarcinomas” [Lung Cancer 126 (2018) 189–193]

Szu-Yen Hu<sup>a</sup>, Min-Shu Hsieh<sup>b</sup>, Hsao-Hsun Hsu<sup>a</sup>, Tung-Ming Tsai<sup>a</sup>, Xu-Heng Chiang<sup>a</sup>, Kuan-Chuan Tsou<sup>c</sup>, Hsien-Chi Liao<sup>d</sup>, Mong-Wei Lin<sup>a,\*</sup>, Jin-Shing Chen<sup>a</sup>

<sup>a</sup> Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan

<sup>b</sup> Department of Pathology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan

<sup>c</sup> Department of Surgery, Taipei City Hospital, Taipei, Taiwan

<sup>d</sup> Department of Traumatology, National Taiwan University Hospital, Taipei, Taiwan

Errors occurred in Table 2, “Association between STAS and clinicopathological characteristics and genetic mutations” which are corrected here. Specifically, the patient number of T1mi and T1a were 61 and 103, respectively. Positive STAS was noted in 11.7% (12/103) of T1a patients, and was not noted in all T1mi patients.

The authors would like to apologize for any inconvenience caused.

Table 2 Association between STAS and clinicopathological characteristics and genetic mutations

Variables	All patients	STAS		p Value
		+	-	
Number of patients	500	134 (26.8)	366	
Tumor size (cm)	1.8	2.5 ± 1.4	1.6 ± 1.2	< 0.001
Differentiation				< 0.001
Well	155	8 (5.2)	147	
Moderate/poor	345	126 (36.5)	219	
Visceral pleural invasion				< 0.001
Positive	70	35 (50.0)	35	
Negative	430	99 (23.0)	331	
Vascular invasion				< 0.001
Positive	83	51 (61.4)	32	
Negative	417	83 (19.9)	334	
Resection margin				0.120
Free	484	127 (26.2)	357	
Involvement	16	7 (43.8)	9	
Predominant subtype				< 0.001
Lepidic	138	11 (8.0)	127	
Non-lepidic	362	123 (34.0)	239	
Acinar	185	52 (28.1)	133	
Papillary	60	20 (33.3)	40	
Micropapillary	32	22 (68.8)	10	
Solid	18	12 (66.7)	6	
Mixed type	34	10 (29.4)	24	

Others	33	7 (21.2)	26	
T stage				< 0.001
Tis-T1a	189	12 (6.4)	177	
Tis	25	0 (0.0)	25	
T1mi	61	0 (0.0)	61	
T1a	103	12 (11.7)	91	
T1b-T4	311	122 (39.2)	189	
T1b	129	41 (31.8)	88	
T1c	73	31 (42.5)	42	
T2	90	40 (44.4)	50	
T3, T4	19	10 (52.6)	9	
N stage				< 0.001
N0	448	101 (22.5)	347	
N1	18	12 (66.7)	6	
N2	34	21 (61.8)	13	
Pathological stage				< 0.001
AIS	25	0 (0.0)	25	
1A1	162	10 (6.2)	152	
1A2	124	38 (30.6)	86	
1A3	57	20 (35.1)	37	
1B	63	25 (39.7)	38	
II	29	18 (62.1)	11	
III	40	23 (57.5)	17	
EGFR				0.003
Positive	269	86 (32.0)	183	
Negative	187	44 (23.5)	143	
N/A	44			
KRAS				0.026
Positive	11	4 (36.4)	7	
Negative	442	125 (28.3)	317	
N/A	47			
BRAF				0.003
Positive	2	2 (100.0)	0	
Negative	451	127 (28.2)	324	
N/A	47			
HER2				0.022
Positive	7	1 (14.3)	6	

DOI of original article: <https://doi.org/10.1016/j.lungcan.2018.11.003>

\* Corresponding author at: Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, No. 7, Chung-Shan South Rd., Taipei, 10002, Taiwan.

E-mail address: [mwlin@ntu.edu.tw](mailto:mwlin@ntu.edu.tw) (M.-W. Lin).

<https://doi.org/10.1016/j.lungcan.2019.03.005>

Negative	446	128 (28.7)	318	
N/A	47	10 (34.5)	19	
<i>ALK</i>				0.002
Positive	13	6 (46.2)	7	
Negative	176	61 (34.7)	115	
N/A	311			

---

Values are presented as n (%) or mean  $\pm$  standard deviation.

Abbreviations: *AIS*, adenocarcinoma in situ; *ALK*, anaplastic lymphoma kinase; *EGFR*, epidermal growth factor receptor; *HER2*, human epidermal growth factor receptor 2; *STAS*, spread through air spaces.